** Shares of healthcare products distributor Henry Schein HSIC.O rise ~4% to $71.94
** BofA Securities upgrades stock to "buy" from "underperform"; raises price objective to $84 from $69
** HSIC stands out as a "best-of-breed dental asset" with a proven ability to grow earnings at healthy rates, similar to its performance before COVID-19, brokerage says
** Company is well-positioned to gain share from both distributors and manufacturers due to its exposure to high-growth dental service organizations (DSO) customers and private label offerings - BofA Securities
** HSIC is positioned for long-term success with "best-in-class portfolio in dental", with above-market exposure to DSO customers - brokerage
** Six of 15 brokerages rate the stock "buy" or higher, 7 "hold" and 2 "sell"; median PT is $75 - data compiled by LSEG
** HSIC fell 8.6% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。